Compare Macy's Inc (M) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs Mesoblast Limited — how do they compare? Macy's Inc trades at $22.88 (market cap $5.95B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Macy's Inc is far larger — about 3.3× Mesoblast Limited's market cap, and Macy's Inc pays a 3.36% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Macy's Inc for 58 Days and Mesoblast Limited for 14 Days on average.
| M | MESO | |
|---|---|---|
Market Cap | $5.95B | $1.81B |
Volume | 11,329,747 | 240,620 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.21 | $20.96 |
52-Week Low | $16.51 | $13.19 |
Typical Hold Time | 58 Days | 14 Days |
Enterprise Value | $9.75B | $1.89B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's stock trades at $22.79, up 1.47% with a bullish technical signal and strong valuation metrics including a P/E of 8.35 and P/S of 0.27. The company has beaten earnings estimates for three consecutive quarters and maintains a 3.5% dividend yield. Recent 'Bold New Chapter' strategy initiatives are showing traction with improved sales and operational metrics.
The stock offers attractive value with upside to the $24.25 consensus target, though Q3 earnings risk and retail sector headwinds remain concerns. Positive cash flow generation and debt reduction support the dividend, while digital transformation efforts provide growth catalysts.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
